Xenon Pharmaceuticals Inc. - Common Stock (XENE) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
XENE on Nasdaq
Shares outstanding
77,331,078
Price per share
$44.82
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
84,320,694
Total reported value
$3,385,186,233
% of total 13F portfolios
0.01%
Share change
+873,660
Value change
+$50,758,270
Number of holders
218
Price from insider filings
$44.82
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Xenon Pharmaceuticals Inc. - Common Stock (XENE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 12% +12% $277,261,485 +$30,579,986 8,824,363 +12% FMR LLC 30 Jun 2025
BlackRock, Inc. 6.2% $148,914,864 4,757,709 BlackRock, Inc. 30 Jun 2025
JANUS HENDERSON GROUP PLC 5.1% $158,346,983 3,943,885 JANUS HENDERSON GROUP PLC 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 2.8% $68,330,991 2,174,761 Wellington Management Group LLP 30 Jun 2025

As of 30 Sep 2025, 218 institutional investors reported holding 84,320,694 shares of Xenon Pharmaceuticals Inc. - Common Stock (XENE). This represents 109% of the company’s total 77,331,078 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) together control 80% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 12% 8,918,907 +0.39% 0.02% $358,094,116
Avoro Capital Advisors LLC 7% 5,400,000 0% 2.8% $216,810,000
BlackRock, Inc. 6.2% 4,770,951 -11% 0% $191,553,697
Driehaus Capital Management LLC 5.4% 4,169,114 -3.8% 1.2% $167,389,927
JANUS HENDERSON GROUP PLC 5.1% 3,943,885 +10% 0.07% $158,311,659
WELLINGTON MANAGEMENT GROUP LLP 4.7% 3,609,857 +66% 0.03% $144,935,758
BRAIDWELL LP 4.7% 3,605,029 0% 4.3% $144,741,914
Capital International Investors 4.1% 3,181,493 -0% 0.02% $127,736,944
Commodore Capital LP 3.5% 2,700,000 -11% 5.3% $108,405,000
Polar Capital Holdings Plc 3.3% 2,546,766 -5.8% 0.49% $102,252,655
Holocene Advisors, LP 2.6% 1,976,553 +9.2% 0.18% $79,358,603
ALLIANCEBERNSTEIN L.P. 2.1% 1,654,417 +8.9% 0.02% $66,424,843
STATE STREET CORP 1.9% 1,466,467 +6.2% 0% $58,878,650
Affinity Asset Advisors, LLC 1.8% 1,400,000 +27% 5.2% $56,210,000
JPMORGAN CHASE & CO 1.8% 1,399,033 +11% 0% $56,171,175
MILLENNIUM MANAGEMENT LLC 1.8% 1,384,007 +57% 0.04% $55,567,881
Pictet Asset Management Holding SA 1.6% 1,262,579 -14% 0.05% $50,584,462
WESTFIELD CAPITAL MANAGEMENT CO LP 1.6% 1,206,066 +4.6% 0.2% $48,423,550
Deep Track Capital, LP 1.6% 1,200,000 -11% 1.3% $48,180,000
JENNISON ASSOCIATES LLC 1.5% 1,135,235 +63% 0.03% $45,579,686
Vestal Point Capital, LP 1.4% 1,100,000 -45% 2% $44,165,000
GEODE CAPITAL MANAGEMENT, LLC 1.3% 977,435 +0.73% 0% $39,240,615
CITADEL ADVISORS LLC 1.2% 959,098 +699% 0.03% $38,507,785
Rock Springs Capital Management LP 1.1% 851,744 -8.6% 2% $34,197,522
VANGUARD GROUP INC 1.1% 851,386 -2.5% 0% $34,183,148

Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 941,735 $42,208,797 +$11,601,010 $44.82 16
2025 Q3 84,320,694 $3,385,186,233 +$50,758,270 $40.15 218
2025 Q2 83,131,091 $2,602,180,922 +$191,395,540 $31.30 206
2025 Q1 76,712,560 $2,576,157,111 +$10,187,791 $33.55 206
2024 Q4 76,301,942 $2,990,887,419 +$29,910,038 $39.20 209
2024 Q3 74,889,394 $2,949,541,361 +$275,979 $39.37 202
2024 Q2 74,169,549 $2,891,734,051 +$25,968,930 $38.99 212
2024 Q1 73,488,096 $3,163,931,600 +$66,663,770 $43.05 220
2023 Q4 72,058,517 $3,319,081,625 +$473,994,183 $46.06 204
2023 Q3 61,366,625 $2,096,353,515 +$8,680,142 $34.16 180
2023 Q2 61,306,738 $2,360,645,061 +$10,880,022 $38.50 173
2023 Q1 61,134,066 $2,185,894,799 +$24,625,634 $35.79 161
2022 Q4 60,466,775 $2,384,173,156 +$38,699,727 $39.43 157
2022 Q3 57,955,532 $2,092,174,527 +$39,481,459 $36.10 151
2022 Q2 57,007,759 $1,734,195,451 +$237,069,658 $30.42 149
2022 Q1 49,043,946 $1,499,284,580 +$44,953,028 $30.57 128
2021 Q4 47,689,350 $1,489,826,062 +$453,547,589 $31.24 129
2021 Q3 34,071,867 $521,082,671 +$347,889 $15.28 113
2021 Q2 33,296,183 $619,964,580 +$2,566,015 $18.62 99
2021 Q1 32,964,044 $590,006,963 +$88,828,095 $17.90 88
2020 Q4 28,020,659 $430,912,842 -$1,905,185 $15.38 79
2020 Q3 27,927,587 $309,203,900 -$546,988 $11.07 79
2020 Q2 27,956,934 $350,580,052 +$8,434,389 $12.54 78
2020 Q1 27,692,215 $313,869,842 +$101,491,596 $11.34 69
2019 Q4 18,704,750 $245,218,634 +$22,437,621 $13.11 66
2019 Q3 16,095,522 $145,000,637 -$14,668,511 $9.01 53
2019 Q2 17,563,087 $173,174,992 -$1,947,261 $9.86 59
2019 Q1 17,736,748 $180,206,294 +$3,000,347 $10.16 61
2018 Q4 17,450,658 $110,112,206 -$24,376,594 $6.31 56
2018 Q3 17,678,662 $234,229,778 +$115,388,474 $13.20 59
2018 Q2 9,038,748 $83,159,306 +$29,134,581 $9.20 41
2018 Q1 6,350,539 $31,098,772 -$13,812,327 $4.90 35
2017 Q4 9,156,573 $25,870,113 -$498,226 $2.83 31
2017 Q3 9,321,729 $27,499,118 -$1,981,003 $2.95 31
2017 Q2 9,948,182 $31,335,126 -$1,135,510 $3.15 39
2017 Q1 10,076,433 $40,304,200 -$3,171,773 $4.00 37
2016 Q4 10,492,956 $80,798,000 +$1,871,735 $7.70 31
2016 Q3 9,943,719 $80,586,000 +$37,001,698 $8.10 31
2016 Q2 5,377,516 $32,048,000 -$2,510,463 $5.90 21
2016 Q1 5,708,042 $39,935,000 -$1,434,240 $6.99 25
2015 Q4 5,776,167 $46,491,000 +$2,273,755 $8.04 25
2015 Q3 5,476,932 $45,239,000 +$5,117,394 $8.26 25
2015 Q2 4,806,596 $55,420,000 +$3,173,766 $11.53 25
2015 Q1 4,449,844 $75,166,316 +$2,920,417 $16.86 23
2014 Q4 4,275,072 $83,141,000 +$76,655,000 $19.75 16